Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Drop in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 266,500 shares, a decline of 64.8% from the January 15th total of 757,800 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average trading volume of 454,900 shares, the days-to-cover ratio is presently 0.6 days.

Sensei Biotherapeutics Price Performance

SNSE traded up $0.01 during trading on Thursday, hitting $0.48. The company’s stock had a trading volume of 156,387 shares, compared to its average volume of 578,429. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94. The stock has a market cap of $12.15 million, a PE ratio of -0.41 and a beta of 0.17. The firm’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.53.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the quarter. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent quarter. Institutional investors own 10.50% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a research note on Wednesday, January 8th.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.